Cargando…

Larotrectinib Response in NTRK3 Fusion-Driven Diffuse High-Grade Glioma

High-grade glioma (HGG) and glioblastoma are the most common adult malignant brain tumors. The standard treatment consists of surgical resection followed by radiochemotherapy with temozolomide. The prognosis and the therapeutic options of these malignant brain tumors however are limited. Here, we de...

Descripción completa

Detalles Bibliográficos
Autores principales:	König, David, Hench, Jürgen, Frank, Stephan, Dima, Laura, Bratic Hench, Ivana, Läubli, Heinz
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	S. Karger AG 2022
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9254302/ https://www.ncbi.nlm.nih.gov/pubmed/35526519 http://dx.doi.org/10.1159/000524399

Ejemplares similares

Fast routine assessment of MGMT promoter methylation
por: Hench, Ivana Bratic, et al.
Publicado: (2020)

Brief Report: Potent clinical and radiological response to larotrectinib in TRK fusion-driven high-grade glioma
por: Ziegler, David S., et al.
Publicado: (2018)

Larotrectinib in NTRK Fusion-Positive High-Grade Glioneuronal Tumor: A Case Report
por: Tadipatri, Ramya, et al.
Publicado: (2022)

Liquid Biopsy in Clinical Management of Breast, Lung, and Colorectal Cancer
por: Hench, Ivana Bratić, et al.
Publicado: (2018)

Satisfying your neuro-oncologist: a fast approach to routine molecular glioma diagnostics
por: Hench, Jürgen, et al.
Publicado: (2018)

Discovery of a rare GKAP1-NTRK2 fusion in a pediatric low-grade glioma, leading to targeted treatment with TRK-inhibitor larotrectinib
por: Deland, Lily, et al.
Publicado: (2021)

Larotrectinib and Entrectinib: TRK Inhibitors for the Treatment of Pediatric and Adult Patients With NTRK Gene Fusion
por: Dunn, Danielle B.
Publicado: (2020)

Antitumor Activity of Larotrectinib in Esophageal Carcinoma with NTRK Gene Amplification
por: Hempel, Dirk, et al.
Publicado: (2020)

A Tissue-Specific Approach to the Analysis of Metabolic Changes in Caenorhabditis elegans
por: Hench, Jürgen, et al.
Publicado: (2011)

Complete Response on Larotrectinib in NTRK2 Fusion-Positive Non-Small Cell Lung Cancer
por: Frehner, Lorenz, et al.
Publicado: (2023)

Antitumor activity of larotrectinib in tumors harboring NTRK gene fusions: a short review on the current evidence
por: Ricciuti, Biagio, et al.
Publicado: (2019)

Durable Clinical Response to Larotrectinib in an Adolescent Patient With an Undifferentiated Sarcoma Harboring an STRN-NTRK2 Fusion
por: Wu, Lawrence W., et al.
Publicado: (2018)

Response and Mechanisms of Resistance to Larotrectinib and Selitrectinib in Metastatic Undifferentiated Sarcoma Harboring Oncogenic Fusion of NTRK1
por: Hemming, Matthew L., et al.
Publicado: (2020)

Succinate Dehydrogenase Upregulation Destabilize Complex I and Limits the Lifespan of gas-1 Mutant
por: Pujol, Claire, et al.
Publicado: (2013)

Antitumor Activity of Larotrectinib in Tumors Harboring NTRK Gene Fusions: A Short Review on the Current Evidence [Corrigendum]
Publicado: (2020)

Cerebral vasculitis mimicking intracranial metastatic progression of lung cancer during PD-1 blockade
por: Läubli, Heinz, et al.
Publicado: (2017)

Complete response to larotrectinib treatment in a patient with papillary thyroid cancer harboring an ETV6‐NTRK3 gene fusion
por: Pitoia, Fabián
Publicado: (2021)

Mitochondrial DNA level, but not active replicase, is essential for Caenorhabditis elegans development
por: Bratic, Ivana, et al.
Publicado: (2009)

Regression of ETV6-NTRK3 Infantile Glioblastoma After First-Line Treatment With Larotrectinib
por: Alharbi, Musa, et al.
Publicado: (2020)

Larotrectinib in a NTRK‐rearranged soft tissue sarcoma in the neoadjuvant setting: A case report
por: Percy, Catherine, et al.
Publicado: (2021)

Identification of dual STRN-NTRK2 rearrangements in a high grade sarcoma, with good clinical response to first-line larotrectinib therapy
por: Lin, Ruihe, et al.
Publicado: (2023)

NTRK-1 fusion in endocervical fibroblastic malignant peripheral nerve sheath tumor marking eligibility for larotrectinib therapy: A case report
por: Wells, A.E., et al.
Publicado: (2019)

A novel NCOR2-NTRK1 fusion detected in a patient of lung adenocarcinoma and response to larotrectinib: a case report
por: Zhang, Lei, et al.
Publicado: (2021)

A rapid and durable response to larotrectinib in a patient with NTRK fusion-positive secretory carcinoma originating from the external auditory canal
por: Ando, Yuichi, et al.
Publicado: (2022)

Mixed response and mechanisms of resistance to larotrectinib in metastatic carcinoma ex pleomorphic adenoma of the parotid harboring an NTRK2 fusion: A case report
por: Pircher, Magdalena, et al.
Publicado: (2021)

NTRK rearranged sarcoma of the bone. Role for larotrectinib in the neoadjuvant setting of an ultra-rare tumor: a case report
por: Palmerini, Emanuela, et al.
Publicado: (2023)

Case report: Complete and durable response to larotrectinib (TRK inhibitor) in an infant diagnosed with angiosarcoma harbouring a KHDRBS1-NTRK3 fusion gene
por: Cervi, Catherine, et al.
Publicado: (2023)

Molecular and clinicopathologic features of gliomas harboring NTRK fusions
por: Torre, Matthew, et al.
Publicado: (2020)

BCR-NTRK2 fusion in a low-grade glioma with distinctive morphology and unexpected aggressive behavior
por: Jones, Karra A., et al.
Publicado: (2019)

HGG-12. A CASE OF PEDIATRIC SPINAL HIGH-GRADE GLIOMA WITH NTRK1 GENE FUSION
por: Morisako, Tamaki, et al.
Publicado: (2020)

NTRK fusions in osteosarcoma are rare and non‐functional events
por: Ameline, Baptiste, et al.
Publicado: (2020)

Mechanisms of targeted therapy resistance in a pediatric glioma driven by ETV6-NTRK3 fusion
por: Keddy, Clare, et al.
Publicado: (2021)

Marked Response to Larotrectinib in Pelvic Spindle Cell Sarcoma With Concurrent TPM3-NTRK1 Fusion and CDK4/MDM2 Amplification: A Case Report
por: Huang, Wen-Kuan, et al.
Publicado: (2023)

The Potential Long-Term Comparative Effectiveness of Larotrectinib and Entrectinib for Second-Line Treatment of TRK Fusion-Positive Metastatic Lung Cancer
por: Roth, Joshua A., et al.
Publicado: (2020)

Efficacy and Safety of Larotrectinib in Patients With Tropomyosin Receptor Kinase Fusion–Positive Lung Cancers
por: Drilon, Alexander, et al.
Publicado: (2022)

NUT midline carcinomas and their differentials by a single molecular profiling method: a new promising diagnostic strategy illustrated by a case report
por: Haefliger, Simon, et al.
Publicado: (2020)

H3K27m3 overexpression as a new, BCL2 independent diagnostic tool in follicular and cutaneous follicle center lymphomas
por: Brune, Magdalena M., et al.
Publicado: (2022)

Response to entrectinib in a malignant glioneuronal tumor with ARHGEF2-NTRK fusion
por: Kurozumi, Kazuhiko, et al.
Publicado: (2022)

Rapid, complete and sustained tumour response to the TRK inhibitor larotrectinib in an infant with recurrent, chemotherapy-refractory infantile fibrosarcoma carrying the characteristic ETV6-NTRK3 gene fusion
por: Bielack, S S, et al.
Publicado: (2019)

A Case of Infant-Type Hemispheric Glioma with NTRK1 Fusion
por: Garcia, Mekka R., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_kms6dfrjh18m1j4li45ucbh6g9